We use a very specialized proprietary platform “CHASSYS®” (Chaperone Seeker System) for the identification and validation of active molecules with the appropriate mechanism of action.

This platform allows for the identification of low molecular weight chemical molecules that act as chaperones, therefore improving the folding and/or stabilizing the tertiary structure of proteins that are the cause of a large proportion of rare diseases.

The lead project of the Company is a small molecule for the treatment of Congenital Erythropoietic Porphyria. This molecule has been granted the status of Orphan Drug both by the EMA and the FDA, and is currently in pre-clinical development with the objective to start clinical trials in 2021.

Website: atlasmolecularpharma.com

OWL has developed a comprehensive set of metabolomics tools, which makes possible the discovery and identification of biomarkers for either research or diagnostics purposes. It is a state of the art technology that combines ultra performance liquid chromatography with mass spectrometry (UPLC-MS). OWL has established a leading position in personalized medicine for liver disease, specifically, non-alcoholic steatohepatitis (NASH) and is currently introducing the first in vitro serum based diagnostic for NAFLD and NASH.

Website: www.owlmetabolomics.com